What it is
An investigational dual glucagon and GLP-1 receptor agonist under clinical development as a once-weekly subcutaneous injection.
How it works
Co-agonism of glucagon and GLP-1 receptors, combining incretin-mediated effects on insulin secretion and satiety with glucagon-mediated effects on hepatic glucose handling and energy expenditure.
Where it's used
Under investigation for obesity and type 2 diabetes in clinical trials, with later-stage development concentrated in China.
Regulatory status
Not FDA-approved; investigational compound in clinical trials.
Tracking it
Mazdutide is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem. with a half-life of about 4.6 days (110 h), a dose log also lets a tracker model the relative amount still in your system between doses. for titrated compounds like this one, a log that records the dose at each step is the difference between knowing your history and guessing it.
Source
Public reference
Last reviewed 2026-06-11